Radiation therapy oncology group p-0014: A phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: Androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy

Urology

Volumn 62, Issue SUPPL. 1, 2003, Pages 95-101

  Pienta, Kenneth J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BUSERELIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ETHINYLESTRADIOL; ETOPOSIDE; FLUOROURACIL; GONADORELIN AGONIST; KETOCONAZOLE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; UFT; VINBLASTINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG WITHDRAWAL; HORMONAL THERAPY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; TUMOR GROWTH; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ARTICLE; BRACHYTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG RESISTANCE; MALE; METHODOLOGY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK; SALVAGE THERAPY; SURVIVAL;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MULTICENTER STUDIES; NEOPLASMS, HORMONE-DEPENDENT; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 1842840798     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2003.10.001     Document Type: Article

References (20)

1. Oh WK, and Kantoff PW: Treatment of locally advanced prostate cancer: is chemotherapy the next step? J Clin Oncol 17: 3664-3675, 1999.
2. Smith DC: Chemotherapy for hormone-refractory prostate cancer. Urol Clin North Am 26: 323-331, 1999.
3. van Tinteran H, and Dalesio O: Systematic overview (meta-analysis) of all randomized trials of treatment of prostate cancer. Cancer 72: 3847-3850, 1993.
4. Maximum androgen blockade in advanced prostate cancer: an overview of randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355: 1491-1498, 2000.
5. Kuyu H, Lee WR, Bare R, et al: Recent advances in the treatment of prostate cancer. Ann Oncol 10: 891-898, 1999.
6. Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84: 39-44, 1998.
7. de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. J Urol 162: 1658-1664, 1999.
8. Van Poppel H, van den Broucke F, Derluyn J, et al: Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results of a randomized trial. J Urol 149: 1485-1487, 1993.
9. Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial. Anticancer Res 19: 2157-2161, 1999.
10. Miyake H, Hara I, Fujisawa M, et al: Comparison of hormonal therapy and chemohormonal therapy in patients with newly diagnosed clinical stage D prostatic cancer. Int J Urol 3: 472-477, 1996.
11. Huben RP, and Murphy GP: A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 62: 1881-1887, 1981.
12. Sakai H, Minami Y, Kanetake H, et al: Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group. Cancer Chemother Pharmacol 35(suppl): S23-S26, 1994.
13. Ono Y, Ohshima S, and Takahashi Y: Endocrine plus uracil/tegafur therapy for prostate cancer. Oncology (Huntingt) 13(suppl 3): 120-124, 1999.
14. Kubota Y, Nakada T, Imai K, et al: Chemo-endocrine therapy in patients with stage D2 prostate cancer. Prostate 26: 50-54, 1995.
15. Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol 8: 1675-1682, 1990.
16. Wang J, Halford S, Rigg A, et al: Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. BJU Int 86: 675-680, 2001.
17. Savarese DM, Halabi S, Hars V, et al: Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 19: 2509-2516, 2001.
18. Petrylak DP, Macarthur R, O'Connor J, et al: Phase I/II studies of docetaxel (Taxotere) with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 26(suppl 17): 28-33, 1999.
19. Smith DC, Dunn RL, Strawderman MS, et al: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16: 1835-1843, 1998.
20. Pienta KJ, Redman BG, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 12: 2005-2012, 1994.